Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23430890 | 1.00 | ANPEP (0.31) | ANPEPLAP3 | |
| SCHEMBL18760884 | 0.92 | — | — | |
| SCHEMBL6236022 | 0.90 | — | — | |
| SCHEMBL19236193 | 0.89 | P2RX7 (0.30) | — | |
| SCHEMBL28552954 | 0.89 | P2RX7 (0.30) | — | |
| SCHEMBL15247177 | 0.89 | P2RX7 (0.30) | — | |
| SCHEMBL18806912 | 0.88 | ANPEP (0.30) | ANPEPLAP3 | |
| SCHEMBL23190567 | 0.88 | — | — | |
| SCHEMBL17128809 | 0.88 | — | — | |
| SCHEMBL24425414 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 775 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2026-05-19 | — | — | US | claimed |
| US-20220263102-A1 | ELIMINATING VOLTAGE DELAY AND STABILIZING IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2022-08-18 | — | — | US | claimed |
| EP-3997748-A1 | ELIMINATION OF VOLTAGE DELAY AND STABILIZATION OF IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK Batterietechnologie GmbH (DE) | 2022-05-18 | — | — | EP | claimed |
| CN-114342141-A | Elimination of voltage delay and stabilization of impedance by electrolyte additives in alkali metal electrochemical cells | 利特罗尼克电池技术有限公司 | 2022-04-12 | — | — | CN | claimed |
| WO-2021004862-A1 | ELIMINATION OF VOLTAGE DELAY AND STABILIZATION OF IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2021-01-14 | — | — | WO | claimed |
| EP-3764434-A1 | ELIMINATION OF VOLTAGE-DELAYS AND STABILISATION OF IMPEDANCE THROUGH ELECTROLYTE ADDITIVES IN ALKALINE METAL CHEMICAL CELLS | LITRONIK Batterietechnologie GmbH (DE) | 2021-01-13 | — | — | EP | claimed |
| EP-4745134-A1 | PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | LITRONIK BATTERIETECHNOLOGIE GMBH (DE) | 2026-05-19 | — | — | US | disclosed |
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4727652-A1 | (HETERO)ARYL-SULFONAMIDE COMPOUNDS AS MODULATORS OF GPR35 | ThirtyFiveBio Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006044823-A2 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060009453-A1 | Protein kinase modulators and method of use | AMGEN INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005113494-A2 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005035533-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009453-A1 | Protein kinase modulators and method of use | PHKG1, PRKCH, BMP2K | ANPEP 3503/4885LAP3 3648/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | ANPEP 4660/4885LAP3 2998/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | ANPEP 2950/4885LAP3 2316/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | ANPEP 3820/4885LAP3 3760/4885 |
| US-12633548-B2 | Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells | KCNN1, HCN4, KCNN2 | ANPEP 3045/4885LAP3 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.